struction (UUO) (2, 73) . The functional complexities of M⌽ can be explained by their phenotypic plasticity in response to varying microenvironmental stimuli determined by the type and stage of the kidney disease. M⌽ infiltration is a common feature of most human chronic kidney diseases. Correlations between the degree of M⌽ infiltration and severity of kidney injury in humans, suggest a pathogenic role of M⌽ in kidney disease (16, 17, 25, 33, 51, 67, 98) . Importantly, proof of a causal role for M⌽ has to be demonstrated in animal studies. Indeed, animal studies have shown an induction of kidney injury by inflammatory mediators released from M⌽, an improvement of kidney injury and function by depletion of M⌽, and an acceleration of kidney injury by repletion of M⌽. In the past decade, the focus of M⌽ studies has expanded to include their potential benefits to immune regulation and tissue repair. M⌽ can be modulated to wound-healing and regulatory phenotypes, which hold therapeutic potential for kidney diseases (7, 15, 87) .
In this review, we summarize current knowledge of the pathogenic and protective roles of kidney M⌽ in acute and chronic kidney diseases. Specific attention will be given to the development of novel M⌽-based strategies to treat human kidney diseases.
PATHOGENIC AND PROTECTIVE ROLE OF M⌽ IN ACUTE KIDNEY DISEASE
IRI. IRI is relevant to a number of clinical situations, including kidney transplantation. M⌽ contribute to IRI by enhancing the inflammatory cascade through secretion of cytokines, recruitment of neutrophils, and induction of epithelial cell apoptosis (50) . Early depletion and reconstitution studies have established a role of M⌽ in kidney IRI (14, 35, 43, 84) . Using liposomal clodronate (LC), Day's studies demonstrated that M⌽ play a critical role in mediating tissue injury from ischemia-reperfusion (IR) in a mouse model of IRI (14) . Later, Kim's group observed similar results by depleting M⌽ by using systemic administration of LC in a rat IRI model (35) and demonstrated that M⌽ contribute to the develop-ment of renal inflammation and fibrosis in the long term after IRI, supporting the negative effects of M⌽ on the repair of postischemic kidneys (43) . Hypoxia occurs not only in IRI but also is present in chronic kidney diseases due to reduction of capillary density in areas of inflammation. M⌽ in a hypoxic kidney microenvironment can be activated to secrete proangiogenic growth factors and proinflammatory cytokines. M⌽ in response to hypoxia also increase secretion of chemokines that promote M⌽ recruitment. Recruited M⌽ themselves could further worsen kidney microenvironmental hypoxia (19, 61, 77) . In contrast to these pro-inflammatory functions, kidney M⌽ have recently been proposed to have a protective role during the repair phase. Lee found that M⌽ expressed pro-inflammatory markers during the initial phase of IRI, whereas M⌽ displayed an alternatively activated phenotype during the repair phase. Depletion of M⌽ before IR (M1 predominance) reduced injury, whereas depletion during IR (M2 predominance) diminished tubular cell proliferation and delayed tubule repair. When M1 M⌽ were adoptively transferred early after injury, they switched to an M2 phenotype within the kidney during the later recovery phase (48) . These findings are consistent with several other published studies in which M⌽ ablation during the repair phase of IRI resulted in deleterious outcomes (38, 52) . Lin found that the mechanism underlying M2 promotion of kidney repair involves production of the Wnt pathway ligand Wnt7b, and M⌽ Wnt7b promotes regeneration via epithelial cell-cycle progression and basement membrane repair ( Fig. 1) (52) . Also CSF-1 mediated resident M⌽ expansion and polarized them toward an M2 phenotype, which resulted in renal tubule epithelial regeneration after AKI (1, 58, 101) . Together, these studies show that M⌽ undergo a switch from a proinflammatory to a trophic phenotype that supports the transition from tubule injury to tubule repair in acute kidney injury.
Unilateral ureteral obstruction. Unilateral ureteral obstruction (UUO) is a model of progressive renal interstitial fibrosis. The severity of fibrosis correlates with infiltration of activated M⌽ (18) , which secrete profibrotic and pro-inflammatory cytokines (40) . Systemic M⌽ depletion 1 day before UUO resulted in reduced initial interstitial M⌽ infiltration and also decreased renal fibrosis, suggesting that the initial phase of M⌽ infiltration may promote renal fibrosis (79) . Similarly, administration of LC selectively depleted both F4/80ϩ M⌽ and F4/80ϩ dendritic cells in mice with UUO but not F4/80Ϫ dendritic cells, resulting in attenuated tubular apoptosis and renal fibrosis and decreased pro-fibrotic cytokines TNF-␣ and TGF-␤ (40) . Yokoyama and colleagues found that blockade of chemokine CCL2 or its receptor CCR2 impeded the initial phase of M⌽ infiltration following UUO and decreased M⌽ infiltration and renal fibrosis (39, 85) . Our group found that MMP-2 and MMP-9 were involved in the epithelial mesenchymal transition (EMT) and thereby contributed to renal fibrosis (Fig. 1) . LPS/IFN-␥-activated M⌽ produce a large amount of MMP-2 and MMP-9, which increased tubular cell EMT via the ␤-catenin pathway. Blockade of MMP-2/MMP-9 or MMP-9 alone attenuated the renal fibrosis in UUO (80, 103) . In contrast, an inverse correlation between the number of interstitial M⌽ and the degree of fibrosis has been found recently in UUO, thereby suggesting an anti-fibrotic role of infiltrating M⌽ in the later recovery phase of obstructive nephropathy (12, 64 -66, 68, 100) . Nishida demonstrated that interstitial M⌽ display an anti-fibrotic role at day 14, but not day 5, after UUO. They found that angiotensin II type 1 receptor (Agtr1) on M⌽ functions in vivo to attenuate renal fibrosis by using wild-type mice reconstituted with Agtr1Ϫ/Ϫ bone marrow. Their data suggest that angiotensin II affects the quantity and phagocytic activity of M⌽ through Agtr1 (64) . The inverse correlation between interstitial M⌽ number and interstitial fibrosis at late stage (day 14) of UUO was confirmed by using cyclophosphamide-mediated M⌽ depletion and matrix metalloproteinase (MMP)-2 inhibitor studies (65, 66) . These findings are consistent with those from the different groups. Zhang demonstrated that the absence of scavenging receptor on uPARϪ/Ϫ M⌽ resulted in the delayed clearance of pro-fibrotic molecules leading to renal fibrosis in the UUO model (100). Thus both pathogenic and protective M⌽ have been reported in UUO in depletion studies. The existence of multiple roles for M⌽ could be explained by depletion of M⌽ of different phenotypes during different stages of UUO. Also, it cannot be excluded that incomplete depletion (usually 50 -70% depletion) of kidney M⌽ leaves behind a M⌽ population with a different composition to that of the original population, resulting in the variable outcomes of depletion studies.
Cisplatin nephrotoxicity. Cisplatin is widely used to treat cancer, and one of its limiting side effects is acute kidney injury characterized by acute tubular necrosis and inflamma- Fig. 1 . Macrophage phenotype and function are critical determinants of kidney injury or repair. In response to ongoing injury, activated pro-inflammatory macrophages (M1) secrete pathogenic factors that induce kidney injury and fibrosis by promoting inflammation and tubular cell apoptosis. In certain microenvironments, anti-inflammatory macrophages (M2) secrete regenerative trophic factors that reduce inflammation, promote cell proliferation, and stimulate angiogenesis, which leads to wound healing and renal recovery. It is unclear whether M2 contribute to kidney fibrosis.
tion. The role of M⌽ in cisplatin nephrotoxicity is uncertain. Treatment of peritoneal M⌽ with cisplatin in vitro induced nitric oxide, pro-inflammatory cytokines, and activation of NF-B (9, 81) . Several recent studies showed a positive correlation between interstitial M⌽ number and degree of kidney injury in cisplatin nephrotoxicity, suggesting a pathogenic role of kidney M⌽ (37, 47, 49, 72) . Ramesh found that cisplatin activates p38 MAPK, which leads to increased production of TNF-␣ in M⌽. Inhibition of p38 MAPK in cisplatin nephrotoxicity resulted in less M⌽ infiltration and kidney injury (72) . Other investigators found that rosiglitazone (a PPARg agonist) and alpha-lipoic acid (an anti-oxidant) decreased infiltration of interstitial M⌽, resulting in functional and histological protection (37, 49) . Moreover, Lee demonstrated that kidney M⌽ accumulation was significantly reduced in mice treated with regulatory T cells, which correlated with less renal dysfunction and tubular injury (47) . All of these data indicate that M⌽ have a pathogenic role in cisplatin-induced kidney injury. However, Lu reported that depletion of M⌽ by LC or inhibition of M⌽ infiltration by CX3CL1 antibody was not sufficient to prevent cisplatin-induced renal dysfunction, suggesting that M⌽ infiltration is a reflection of the severity of injury rather than its cause (54) .
Taken together, current data suggest a phase-dependent balance of pro-inflammatory M⌽ (M1) and anti-inflammatory M⌽ (M2) in kidney diseases. M1 M⌽ play a predominant pathogenic role during the early stage of acute kidney injury and contribute to acute tubular necrosis and inflammation. Subsequently, M2 M⌽ predominate at a later stage of acute kidney injury and contribute to wound healing and resolution of inflammation (Table 1) .
PATHOGENIC AND PROTECTIVE ROLE OF M⌽ IN CHRONIC KIDNEY DISEASE
Anti-glomerular basement membrane glomerulonephritis. M⌽ accumulation within the kidney is a prominent feature in most forms of human glomerulonephritis (GN). Glomerular M⌽ secrete proinflammatory cytokines, reactive oxygen radicals, and nitric oxide, which are critical mediators of further glomerular damage and proteinuria (62) . Early studies by Holdsworth (26, 27) demonstrated that M⌽ accumulated in glomeruli in direct response to the deposition of antibody in anti-glomerular basement membrane (GBM) glomerulonephritis. Inhibition of M⌽ accumulation by anti-M⌽ serum largely prevented progression of experimental glomerulonephritis (26, 27) . M⌽ depletion by clodronate microspheres resulted in 95% depletion of M⌽ from kidney and greatly reduced TNF-␣ and IL-1␤ release in anti-GBM glomerulonephritis. These data suggest that activated M⌽ mediated the kidney damage in GN through release of pro-inflammatory cytokines ( Fig. 1) (13) . Studies by Nikolic-Paterson used adoptive transfer of M⌽ to investigate their role in kidney disease. They found that adoptive transfer of bone marrow M⌽ directly mediated mesangial cell proliferation and proteinuria in acute anti-GBM nephritis (30, 32) . Exposure of M⌽ to a specific Jun amino terminal kinase (JNK) inhibitor before adoptive transfer caused a Ͼ70% reduction in proteinuria and glomerular cell proliferation in this model (31) . In the chronic anti-GBM model, early or late treatment with a specific JNK inhibitor reduced proteinuria and suppressed glomerular and tubulointerstitial damage (20, 55) . These studies suggest that inhibition of JNK signaling protects against kidney injury in acute and chronic phases of anti-GBM disease, partially via suppression of the M⌽ proinflammatory response. A recent study has provided clearer evidence of M⌽-mediated kidney injury. A specific M⌽ colony-stimulating factor receptor (c-fms) inhibitor completely reversed M⌽ infiltration and prevented kidney injury in anti-GBM disease (24) .
Lupus nephritis. Lupus nephritis is a major cause of morbidity and mortality in patients with systemic lupus erythematosus. Progression of kidney injury is related to infiltration of M⌽ and lymphocytes (45) . M⌽ secrete a wide array of molecules that could cause kidney injury, including reactive oxygen species, nitric oxide, pro-inflammatory cytokines, and growth factors. IFN-␥ produced by infiltrating M⌽ has been found to be responsible for adhesion molecule upregulation and kidney M⌽ accumulation (8) . CCL2 is expressed highly in lupus nephritis and is crucial for monocyte recruitment into sites of inflammation. Blockade of CCL2 or CCR2 using inhibitors or knockout mice significantly reduced M⌽ infiltration with a remarkable reduction of tissue injury in MRL/lpr mice (44, 69) . Colony stimulating factor-1 (CSF-1), a primary Early studies showed that blockade of CCR1, CCL2, or CCL5 by specific antagonists or DNA vaccination markedly reduced the infiltration of M⌽ and kidney injury in AN mice, suggesting a pathogenic role of M⌽ in AN (83, 94, 104) . Studies by our group found that M⌽ depletion in AN protected both renal function and structure, providing direct evidence that M⌽ play a pathogenic role in kidney injury of AN (88) . Further studies have investigated the role of M⌽ in AN by using adoptive transfer. Adoptive transfer of CpG DNA activated M⌽ (M1), but not resting M⌽ (M0), exacerbated kidney injury in AN mice (86) . Recently, targeting IL-18 derived from infiltrating M⌽ by a neutralizing binding protein protected against the development of AN, with less proteinuria, glomerulosclerosis, and interstitial inflammation (95) .
Alport nephropathy. Alport disease is induced by genetic mutations of the ␣3, ␣4, or ␣5 chains of type IV collagen, which impairs the proper assembly of glomerular basement membrane. Progression of Alport nephropathy is associated with M⌽ infiltrates in the glomerular and the interstitial compartments. Ninichuk and colleagues (63) demonstrated that delayed CCR1 blockade improved survival of Col4␣3-deficient mice, which was associated with less interstitial M⌽.
They found that BX471, a small molecule CCR1 antagonist, completely blocked CCL3-induced CCL5 production in activated murine M⌽. Reduction of interstitial M⌽ was associated with decreased tubular cell apoptosis and increased tubular cell proliferation, suggesting that interstitial M⌽ play a role in the balance of apoptotic cell death and tubular cell regeneration (63) . However, Clauss (11) found that CCL2 blockade reduced glomerular and interstitial M⌽ but did not ameliorate glomerular damage in Col4␣3-deficient mice with Alport nephropathy, implying that M⌽ do not contribute significantly to glomerular pathology in this model. Blockade of CCR1, but not CCR2, improved renal pathology in Col4␣3-deficient mice, suggesting that CCR1ϩ M⌽, but not CCR2ϩ M⌽, are predominant pathogenic M⌽ in this model of Alport nephropathy (11) . A further study by the same group found that bacterial CpG-DNA accelerated Alport nephropathy and reduced the overall lifespan of Col4␣3-deficient mice. This effect was associated with a significant increase in kidney classically activated (M1) M⌽, which produce high levels of inducible nitric oxide synthase, TNF-␣, and IL-12. The study suggested that activated kidney M⌽ promote the progression of Alport nephropathy (74) .
Thus current evidence suggests that kidney M⌽ accelerate kidney injury in most types of chronic kidney disease. However, a type II-activated M⌽ (M2b) was identified as a marker of disease remission in lupus nephritis, and an alternatively activated M⌽ (M2a) mediated dysregulated tissue repair in poly (I:C)-induced lupus nephritis (Table 1) . It is likely that, whereas pro-inflammatory and anti-inflammatory kidney M⌽ coexist in chronic kidney diseases, pro-inflammatory M⌽ predominate and result in long-lasting inflammation and progressive kidney injury.
THE POTENTIAL FOR M⌽ THERAPY IN KIDNEY DISEASE
M⌽ comprise a heterogeneous population of cells, with diverse functions and phenotypic plasticity. Based on a new understanding of the diverse biological functions of M⌽, they are no longer regarded merely as effectors of kidney injury but also as potential therapeutic tools that can regulate inflammation and improve renal function. M⌽ that secrete trophic factors and anti-inflammatory cytokines and promote tissue repair have been referred to as regulatory M⌽. Adoptive transfer of regulatory M⌽ has been applied as a treatment of experimental kidney diseases. M⌽ can be modulated to a protective phenotype by either genetic manipulation or by cytokines (Table 2 ). Genetic manipulation of M⌽. M⌽ activity can be modulated by transfer of suppressive genes using viral vectors. Genetically engineered M⌽ can deliver genes specifically to sites of inflammation by following natural chemotactic signals. For example, M⌽ transduced with adenovirus expressing IL-1ra reduced glomerular and tubulointerstitial fibrosis in both anti-GBM glomerulonephritis and obstructive nephropathy (97, 99) . Kluth and colleagues showed that M⌽ transfected with adenovirus expressing IL-4 or IL-10 localized efficiently to inflamed glomeruli of rats with nephrotoxic nephritis and reduced inflammatory cell infiltration and the degree of glomerular injury (41, 93) . IL-10-expressing M⌽ were more effective than those expressing IL-4 (92) . A recent study found that M⌽ transduced with IL-10 can protect against renal ischemia injury through induction of lipocalin-2 (36). Wilson showed that M⌽ transduced with inhibitor of protein kB (IB), which blocks NF-B proinflammatory signaling, reduced IL-12 and TNF-␣ synthesis and NO generation of M⌽ stimulated with LPS and increased IL-10 synthesis (91). These modulated M⌽ also significantly reduced kidney injury in nephrotoxic nephritis. One advantage of genetically engineered M⌽ is their potential for long-lasting expression of target genes. Another advantage of these M⌽ is their ability to deliver genes to sites of injury and inflammation by following natural chemotactic signals. However, major obstacles to future clinical application of genetic modulated M⌽ include the unproven safety of viral vectors and difficulty in controlling the level of gene expression.
Cytokine alteration of M⌽ phenotype. Protective M⌽ also can be induced by cytokines. Such M⌽ have been subdivided into at least three groups: M2a M⌽ induced by IL-4 and/or IL-13; M2b M⌽ induced by immune complexes with LPS; and M2c M⌽ induced by IL-10 and/or TGF-␤. Our group first examined the role of M2 M⌽ in mice with adriamycin nephropathy (AN). In that study, M⌽ were isolated from spleen and incubated with IL-4 and IL-13 to induce an M2a phenotype. The M2a M⌽ significantly protected AN mice against kidney injury that was associated with reduced accumulation and downregulated inflammatory cytokine expression of hostinfiltrating M⌽ (89) . A further study showed the protective effects of M2a M⌽ on kidney injury in another model, that of murine streptozotocin-induced diabetes nephropathy (102) . Similarly, M2a M⌽ transfusion of diabetic endothelial nitric oxide synthase-null (eNOS Ϫ/Ϫ ) mice resulted in reduction of glomerulosclerosis and arteriolar hyalinosis. Another recent study demonstrated that M2a M⌽ promoted renal tubular cell proliferation and reduced kidney damage in mice with IRI (48). Our group has investigated the relative protective efficacy of M2a and M2c M⌽ in AN (6) . M2c M⌽ displayed a greater protective effect than M2a M⌽ against kidney injury, which could relate to the observation that M2c M⌽, but not M2a M⌽, induced Tregs both in culture and in kidney draining lymph nodes. We have investigated mechanisms underlying the protective effect of M2 M⌽ in several studies (6, 89, 102) . Both M2a M⌽ and M2c M⌽ can inhibit CD4 T cells, CD8 T cell proliferation, and resident inflammatory M⌽. However, as discussed above, M2c M⌽ but not M2a M⌽ can induce Tregs. Cytokine-modified M⌽ have the potential to provide a relatively easy and safe approach to treat kidney diseases.
FRONTIERS OF KIDNEY MACROPHAGE RESEARCH
Regulatory M⌽. There is compelling evidence that M⌽ play an important role in tissue damage in kidney diseases. However, during the last decade, attention has been drawn to the antiinflammatory and reparative roles of M⌽. Among acute kidney diseases, M2 M⌽ appear in kidney during recovery of diseases, including IRI and UUO (12, 48, 64) , to play a predominant role in resolution of kidney inflammation and wound healing. Thus it is worth exploring whether M2 M⌽ could be not only a mediator but also a marker of remission of kidney injury in acute kidney disease. Kidney M2 M⌽ have not been reported convincingly in chronic kidney diseases except lupus nephritis (76, 82) . Moreover, in lupus nephritis, M2 M⌽ coexist with but are outnumbered by M1 M⌽, perhaps suggesting only a minor role for M2 M⌽. In chronic kidney disease, it is possible that the relative paucity of M2 M⌽ may be one factor explaining the progressive nature of kidney injury. Therefore, the appearance of M2 M⌽ should be correlated with the severity of CKD, and M2 M⌽ number and activity could be manipulated as a means of slowing disease progression.
Tissue-specific M⌽. Kidney M⌽ display phenotypic heterogeneity in different types of kidney disease and in different stages of disease, which could relate to kidney microenvironment. However, the phenotypic heterogeneity of kidney M⌽ also could be due to their localization in specific kidney compartments, including the glomerulus, periglomerular region, interstitium, cortex, and medulla. M⌽ in different kidney compartments could be affected by unique position-specific microenvironments created by tissue factors. As a result, the effects of M⌽ in glomeruli, for example, may be different from those of M⌽ in interstitium. It is important to define the roles of M⌽ in different kidney sites in various kidney diseases.
Signaling pathways and kidney M⌽ function. The phenotype and function of kidney M⌽ depend in part on the microenvironments in which they reside. Kidney M⌽ can be stimulated into an M1 phenotype by a wide variety of immunological and stress stimuli via various signaling pathways, including c-Jun amino terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK), and activation of nuclear factor-B (NF-B). P38 MAPK and JNK have been demonstrated to be pivotal in M1 M⌽-mediated kidney injury in glomerulonephritis (20, 31, 55, 72) . Other signaling molecules, including suppressor of cytokine signaling 3 (SOCS3) and IKK, have also been reported to be upregulated in kidney M⌽ in nephritis (4, 53) . Recently, it was reported that kidney M⌽ in UUO highly express mTOR signaling and that rapamycin inhibited inflammatory activity of M⌽ via mTOR signaling (10) . However, the signaling pathways involved in M2 M⌽ function in kidney disease remain unclear. In nonrenal diseases, other signaling pathways have been reported to be important in control of M1 and M2 phenotypes, including, among others, those of C/EBP␤, PPAR␥, IRF family, and STAT family, but as yet they have not been studied in kidney diseases (21, 46, 71, 75, 90, 96) . Several novel signaling molecules, including, among others, ATF3, Kif4, and HIF-1␣, were found by our group to be highly expressed in M1, M2a, or M2c M⌽, respectively (Wang C, Cao Q, Lee VW, Zheng G, Alexander SI, Harris DC, and Wang Y., unpublished observations). Future studies need to focus on the signaling pathways and transcription factors related to M⌽ phenotype and function in kidney disease.
Therapeutic targeting kidney M⌽. Specific targeting pathogenic effector M1 M⌽ rather than renal M⌽ as whole is required for optimal therapeutic outcomes. Treatment to target inflammatory signaling pathways of M1 M⌽, including NF-B, JNK, and c-fms, has already been developed (1, 20, 24, 55, 56) . However, to optimally target kidney injury by depletion of specific subtypes of M⌽, it is necessary to define surface markers and signaling pathways with greater specificity for M⌽ phenotypes. Alternatively, transfer of regulatory M⌽ (6, 89) or switch of M⌽ to an M2 phenotype (5) has been demonstrated to be an effective strategy to reduce kidney inflammation and injury in experimental chronic kidney diseases. Despite a reported in vitro pro-fibrotic effect of wound-healing M⌽, our studies demonstrated that M2a and M2c M⌽ reduced kidney fibrosis in mice with Adriamycin nephritis. This paradox needs to be unravelled in greater depth and explored in other disease models, and is likely to have important implications for therapy.
Subset and source of M⌽ determine therapeutic outcome. Transfer of M2 M⌽ has been shown to reduce kidney injury in several models of kidney disease (48, 89, 102) . Interestingly, we showed that M2c M⌽ are more effective than M2a M⌽ in reducing injury in Adriamycin nephropathy, a difference that has not yet been explored in other models. We also found that, unlike M2a M⌽ derived from spleen, M2a M⌽ derived from bone marrow were not protective, apparently due to continued proliferation and loss of protective phenotype within inflamed kidney (Cao Q, Zheng D, Wang C, Wang X, Lee VW, Zheng G, Alexander SI, Wang Y, and Harris DC., unpublished observations). These findings suggest that the therapeutic efficacy of M2 M⌽ depends on both their subtype and their source. The therapeutic effects of different M⌽ subsets and M⌽ from different sources should be examined in various kidney diseases.
Translation of M⌽ therapy to human kidney disease. Regulatory M⌽ possess anti-inflammatory and immune suppressive functions, which endow them with great potential for treating human kidney disease. Recently, a regulatory macrophage (Mreg) was generated in vitro by exposure of blood monocytes to M-CSF and IFN-␥ applied to patients undergoing kidney transplantation and appeared to be successful in reducing the dose of immunosuppressive drugs (28, 29) . Based on this pilot experience, a trial (The One Study; http://www.onestudy.org/) of M⌽ therapy in renal transplantation has commenced. This recent progress lays the foundation for the future therapeutic use of M2 M⌽ in human CKD (34) . It suggests that regulatory M⌽ may provide a real and practicable option for treatment of CKD.
In conclusion, based on numerous recent studies, kidney M⌽, by engaging both innate and adaptive immune responses, are believed to play both pathogenic and protective roles in acute and chronic kidney diseases. Careful dissection of the role of M⌽ at different stages of various kidney diseases should help to elucidate this complex field and lead to the development of novel diagnostic and therapeutic tools. Increasing evidence suggests an important protective role for regulatory M⌽ in dampening kidney injury. Before M⌽ can become a therapeutic target or tool for human kidney disease, there needs to be a much greater understanding of the biology of these plastic, phenotypically diverse cells. 
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